Tjalf Ziemssen

List of Publications by Year
in descending order

355 papers	11,879 citations	31976 53 h-index	46799 89 g-index
416 all docs	416 docs citations	416 times ranked	12337 citing authors

#	Article	IF	Citations
1	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 608-619.	3.0	13
2	Cost of illness in multiple sclerosis by disease characteristics â€“ A review of reviews. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 177-195.	1.4	10
3	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Multiple Sclerosis Journal, 2022, 28, 1131-1137.	3.0	13
4	A role of the norepinephrine system or effort in the interplay of different facets of inhibitory control. Neuropsychologia, 2022, 166, 108143.	1.6	7
5	The need for a strategic therapeutic approach: multiple sclerosis in check. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232110630.	2.5	14
6	Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not. Scientific Reports, 2022, 12, 1446.	3.3	7
7	Long-term real-world effectiveness and safety of fingolimod over 5Âyears in Germany. Journal of Neurology, 2022, 269, 3276-3285.	3.6	10
8	Time-On-Task Effects on Working Memory Gating Processesâ€”A Role of Theta Synchronization and the Norepinephrine System. Cerebral Cortex Communications, 2022, 3, tgac001.	1.6	6
9	Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations. Movement Disorders, 2022, 37, 1074-1079.	3.9	16
10	Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITIONâ€•A 2-Year, Multicenter, Observational, Cohort Study. Brain Sciences, 2022, 12, 215.	2.3	3
11	Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210857.	1.0	2
12	Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. Neurodegenerative Disease Management, 2022, 12, 93-107.	2.2	1
13	Digital Innovation in Multiple Sclerosis Management. Brain Sciences, 2022, 12, 40.	2.3	4
14	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	3.0	13
15	Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their RebismartÂ® Injector: Results of the Prospective Cohort Study REBIFLECT. Advances in Therapy, 2022, 39, 2749-2760.	2.9	6
16	Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wiener Medizinische Wochenschrift, 2022, 172, 365-372.	1.1	10
17	Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study. Frontiers in Neurology, 2022, 13, .	2.4	2
18	FastCAT Accelerates Absolute Quantification of Proteins Using Multiple Short Nonpurified Chimeric Standards. Journal of Proteome Research, 2022, 21, 1408-1417.	3.7	2

#	Article	IF	Citations
19	Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210903.	3.5	1
20	Transparent Quality Optimization for Machine Learning-Based Regression in Neurology. Journal of Personalized Medicine, 2022, 12, 908.	2.5	0
21	Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany. Journal of Personalized Medicine, 2022, 12, 1100.	2.5	3
22	How to reduce the delay of diagnosing secondary progression in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 646-647.	3.0	3
23	Comparative study of microvascular function: Forearm blood flow versus dynamic retinal vessel analysis. Clinical Physiology and Functional Imaging, 2021, 41, 42-50.	1.2	2
24	Dissonance in Music Impairs Spatial Gait Parameters in Patients with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 363-372.	2.8	1
25	Fear of falling and falls in people with multiple sclerosis: A literature review. Multiple Sclerosis and Related Disorders, 2021, 47, 102609.	2.0	26
26	A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. Journal of Neurology, 2021, 268, 1210-1221.	3.6	87
27	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110396.	3.5	86
28	Relation of retinal and hippocampal thickness in patients with amnestic mild cognitive impairment and healthy controls. Brain and Behavior, 2021, 11, e02035.	2.2	6
29	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098213.	3.5	30
30	Impedimetric Microfluidic Sensorâ€inâ€aâ€Tube for Labelâ€Free Immune Cell Analysis. Small, 2021, 17, e2002549.	10.0	23
31	Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study. Seizure: the Journal of the British Epilepsy Association, 2021, 85, 1-5.	2.0	18
32	Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice. Brain Sciences, 2021, 11, 180.	2.3	29
33	Differential longitudinal changes of neuronal and glial damage markers in anorexia nervosa after partial weight restoration. Translational Psychiatry, 2021, 11, 86.	4.8	20
34	Delayed retinal vein recovery responses indicate both non-adaptation to stress as well as increased risk for stroke: the SABPA study. Cardiovascular Journal of Africa, 2021, 32, 7-18.	0.4	5
35	Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECTÂ® Autoinjector: A Prospective Observational Cohort Study. Frontiers in Neurology, 2021, 12, 643126.	2.4	6
36	Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients. Frontiers in Neurology, 2021, 12, 637107.	2.4	6

#	Article	IF	Citations
37	B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e980.	6.0	6
38	Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 650530.	2.4	5
39	CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy. Frontiers in Neurology, 2021, 12, 647428.	2.4	10
40	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research, 2021, 23, e29558.	4.3	8
41	Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110046.	1.0	6
42	Digital Twins for Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 669811.	4.8	108
43	Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. Acta Neuropathologica Communications, 2021, 9, 81.	5.2	19
44	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease. Journal of Personalized Medicine, 2021, 11, 392.	2.5	8
45	CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study. Brain Pathology, 2021, 31, e12969.	4.1	10
46	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 701752.	4.8	17
47	Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment. Brain Sciences, 2021, 11, 786.	2.3	8
48	The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0. Journal of Personalized Medicine, 2021, 11, 561.	2.5	4
49	Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs. International Journal of Molecular Sciences, 2021, 22, 8042.	4.1	19
50	Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study. Frontiers in Neurology, 2021, 12, 620758.	2.4	5
51	Innovation in Digital Education: Lessons Learned from the Multiple Sclerosis Management Masterâ€™s Program. Brain Sciences, 2021, 11, 1110.	2.3	3
52	Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers. Brain Sciences, 2021, 11, 1087.	2.3	10
53	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurological Research and Practice, 2021, 3, 44.	2.0	9
54	Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis. Brain Sciences, 2021, 11, 1049.	2.3	12

#	Article	IF	Citations
55	Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Annals of Clinical and Translational Neurology, 2021, 8, 2013-2024.	3.7	30
56	Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion. Journal of the Neurological Sciences, 2021, 429, 118063.	0.6	3
57	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199399.	3.5	12
58	Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa. Psychoneuroendocrinology, 2021, 135, 105576.	2.7	5
59	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. Frontiers in Immunology, 2021, 12, 715195.	4.8	1
60	Serological Biomarker Profiles of Neurofilament Light Chain in Children and Adolescents with Spinal Muscular Atrophy and Healthy Controls. Neuropediatrics, 2021, 52, .	0.6	0
61	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. Cells, 2021, 10, 3177.	4.1	16
62	Digital Biomarkers in Multiple Sclerosis. Brain Sciences, 2021, 11, 1519.	2.3	38
63	Automated Analysis of the Two-Minute Walk Test in Clinical Practice Using Accelerometer Data. Brain Sciences, 2021, 11, 1507.	2.3	4
64	Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis. Cells, 2021, 10, 3116.	4.1	8
65	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. Frontiers in Immunology, 2021, 12, 715195.	4.8	14
66	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	1.0	3
67	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies. Frontiers in Neuroscience, 2021, 15, 791670.	2.8	2
68	Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. Multiple Sclerosis Journal, 2020, 26, 48-56.	3.0	36
69	Response to Hyun J.W. et al. â€œLongitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosisâ€• Multiple Sclerosis Journal, 2020, 26, 742-743.	3.0	1
70	Letter to the editor regarding â€œTherapeutic drug monitoring of natalizumabâ€• Multiple Sclerosis Journal, 2020, 26, 741-742.	3.0	0
71	Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101503.	2.0	7
72	Diroximel fumarate (DRF) in patients with relapsingâ€“remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis Journal, 2020, 26, 1729-1739.	3.0	41

#	Article	IF	Citations
73	Efficacy of alemtuzumab over 6â€‰years in relapsingâ€“remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal, 2020, 26, 1719-1728.	3.0	13
74	Differentiating societal costs of disability worsening in multiple sclerosis. Journal of Neurology, 2020, 267, 1035-1042.	3.6	34
75	Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 38, 101859.	2.0	6
76	Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab. Multiple Sclerosis and Related Disorders, 2020, 39, 101893.	2.0	11
77	A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physiciansâ€™ and patientsâ€™ views. Multiple Sclerosis and Related Disorders, 2020, 38, 101861.	2.0	29
78	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple Sclerosis Journal, 2020, 26, 1866-1876.	3.0	16
79	The role of TH17 cells in multiple sclerosis: Therapeutic implications. Autoimmunity Reviews, 2020, 19, 102647.	5.8	144
80	The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study. Multiple Sclerosis and Related Disorders, 2020, 46, 102523.	2.0	6
81	Patientâ€•versus physicianâ€reported relapses in multiple sclerosis: insights from a large observational study. European Journal of Neurology, 2020, 27, 2531-2538.	3.3	12
82	The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice. Frontiers in Neuroscience, 2020, 14, 582046.	2.8	11
83	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Frontiers in Neurology, 2020, 11, 632.	2.4	52
84	A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Doseâ€”Possible Predictors of Cardiac Outcomes. Frontiers in Neurology, 2020, 11, 818.	2.4	7
85	Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. CNS Drugs, 2020, 34, 973-988.	5.9	37
86	No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis. Frontiers in Cell and Developmental Biology, 2020, 8, 567659.	3.7	2
87	Why Cognitiveâ€“Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice. Frontiers in Neurology, 2020, 11, 905.	2.4	3
88	Autoantibodies against central nervous system antigens in a subset of B cellâ€“dominant multiple sclerosis patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21512-21518.	7.1	36
89	Gender disparities in health resource utilization in patients with relapsingâ€“remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096027.	3.5	9
90	On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Deviceâ€”A Proof of Concept Study in Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 3423.	2.4	1

#	Article	IF	Citations
91	Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis. Pharmacoeconomics, 2020, 38, 883-892.	3.3	10
92	Visual Feedback and Postural Control in Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 1291.	2.4	11
93	Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration. Frontiers in Neurology, 2020, 11, 391.	2.4	8
94	Quality of Life Improves with Alemtuzumab Over 6ÂYears in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2020, 9, 443-457.	3.2	4
95	Data Collection in Multiple Sclerosis: The MSDS Approach. Frontiers in Neurology, 2020, 11, 445.	2.4	20
96	Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study . Patient Preference and Adherence, 2020, Volume 14, 869-880.	1.8	16
97	A Digital Patient Portal for Patients With Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 400.	2.4	22
98	Clinical outcome measures in multiple sclerosis: A review. Autoimmunity Reviews, 2020, 19, 102512.	5.8	98
99	Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts â€“ the CONFIDENCE study protocol. BMC Neurology, 2020, 20, 95.	1.8	20
100	Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 5941.	3.3	59
101	Balance Testing in Multiple Sclerosisâ€”Improving Neurological Assessment With Static Posturography?. Frontiers in Neurology, 2020, 11, 135.	2.4	17
102	Properties of lower level processing modulate the actions of the norepinephrine system during response inhibition. Biological Psychology, 2020, 152, 107862.	2.2	4
103	Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 56.	4.8	20
104	How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physiciansâ€™ Preferences . Patient Preference and Adherence, 2020, Volume 14, 267-276.	1.8	6
105	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsingâ€“Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. CNS Drugs, 2020, 34, 185-196.	5.9	80
106	A possible role of the norepinephrine system during sequential cognitive flexibility â€“ Evidence from EEG and pupil diameter data. Cortex, 2020, 128, 22-34.	2.4	10
107	Editorial: Cognitive Disorders in Neuroimmunological Diseases. Frontiers in Neurology, 2020, 11, 169.	2.4	1
108	Should We Use Clinical Tools to Identify Disease Progression?. Frontiers in Neurology, 2020, 11, 628542.	2.4	17

#	Article	IF	Citations
109	Longâ€term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Annals of Clinical and Translational Neurology, 2020, 7, 2199-2212.	3.7	40
110	Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. Parkinsonism and Related Disorders, 2020, 80, 28-31.	2.2	6
111	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732097213.	1.0	9
112	A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Td (	4.3	40
113	A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm. JMIR Medical Informatics, 2020, 8, e17592.	2.6	11
114	The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study. Journal of Medical Internet Research, 2020, 22, e17921.	4.3	23
115	Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA. JMIR Research Protocols, 2020, 9, e19598.	1.0	16
116	Peripheral nerve field stimulation in medically refractory trigeminal neuralgia attributed to multiple sclerosis. Journal of Neurosurgery, 2020, 134, 1-7.	1.6	4
117	Spectral Analysis of Heart Rate Variability: Time Window Matters. Frontiers in Neurology, 2019, 10, 545.	2.4	99
118	Early central vs. peripheral immunological and neurobiological effects of fingolimodâ€”a longitudinal study. Journal of Molecular Medicine, 2019, 97, 1263-1271.	3.9	8
119	Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. Journal of Molecular Medicine, 2019, 97, 1547-1555.	3.9	13
120	Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition. Brain Structure and Function, 2019, 224, 1291-1300.	2.3	35
121	Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. Neurodegenerative Disease Management, 2019, 9, 1-2.	2.2	1
122	Review: Patient-reported outcomes in multiple sclerosis care. Multiple Sclerosis and Related Disorders, 2019, 33, 61-66.	2.0	94
123	How the depth of processing modulates emotional interference â€“ evidence from EEG and pupil diameter data. Cognitive, Affective and Behavioral Neuroscience, 2019, 19, 1231-1246.	2.0	9
124	Response to: Kobayashi etÂal.: â€œErythroblast appearance associated with natalizumabâ€•Multiple Sclerosis and Related Disorders 2019. Multiple Sclerosis and Related Disorders, 2019, 32, 114-115.	2.0	1
125	Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e555.	6.0	87
126	Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231983513.	2.5	9

#	Article	IF	Citations
127	Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. Journal of Central Nervous System Disease, 2019, 11, 117957351983199.	1.9	15
128	On the interrelation of 1/f neural noise and norepinephrine system activity during motor response inhibition. Journal of Neurophysiology, 2019, 121, 1633-1643.	1.8	30
129	The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous Systemâ€"A Review. Frontiers in Neurology, 2019, 10, 53.	2.4	107
130	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in Neurology, 2019, 10, 253.	2.4	17
131	Real-world persistence and benefitâ€"risk profile of fingolimod over 36 months in Germany. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e548.	6.0	27
132	Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641989207.	3.5	15
133	Molecular biomarkers in multiple sclerosis. Journal of Neuroinflammation, 2019, 16, 272.	7.2	158
134	Mutually reinforcing effects of genetic variants and interferonâ€Î² 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients. Pulmonary Circulation, 2019, 9, 1-6.	1.7	9
135	Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?. Hormone and Metabolic Research, 2019, 51, 779-784.	1.5	9
136	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
137	How minimal variations in neuronal cytoskeletal integrity modulate cognitive control. NeuroImage, 2019, 185, 129-139.	4.2	25
138	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	3.0	55
139	Multiple sclerosis registries in Europe â€" An updated mapping survey. Multiple Sclerosis and Related Disorders, 2019, 27, 171-178.	2.0	47
140	Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures. NeuroImage: Clinical, 2019, 21, 101623.	2.7	20
141	Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. CNS Drugs, 2019, 33, 61-79.	5.9	31
142	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. Journal of Autoimmunity, 2018, 90, 116-131.	6.5	64
143	Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561774884.	3.5	11
144	Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach. Expert Opinion on Drug Safety, 2018, 17, 369-378.	2.4	32

#	Article	IF	Citations
145	Determination of Seminal Concentration of Fingolimod and Fingolimodâ€Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod. Clinical Pharmacology in Drug Development, 2018, 7, 217-221.	1.6	5
146	Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefitâ€"Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA. Neurotherapeutics, 2018, 15, 190-199.	4.4	12
147	Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€•Multiple Sclerosis and Related Disorders 2017. Multiple Sclerosis and Related Disorders, 2018, 22, 68-69.	2.0	1
148	Letter to the editor to the paper: â€œAcute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosisâ€• Multiple Sclerosis and Related Disorders, 2018, 22, 57-58.	2.0	0
149	Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875989.	3.5	1
150	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238
151	The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas. Brain Structure and Function, 2018, 223, 925-940.	2.3	33
152	Natalizumab during pregnancy and lactation. Multiple Sclerosis Journal, 2018, 24, 1627-1634.	3.0	48
153	Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurologica Scandinavica, 2018, 137, 356-362.	2.1	71
154	Letter to the editor on the paper: â€œThe majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosingâ€• Multiple Sclerosis Journal, 2018, 24, 820-822.	3.0	1
155	Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up. Frontiers in Neurology, 2018, 9, 1071.	2.4	30
156	Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients. Frontiers in Immunology, 2018, 9, 2669.	4.8	30
157	Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology, 2018, 91, 849-850.	1.1	1
158	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs, 2018, 32, 1159-1171.	5.9	38
159	Sudomotor Testing of Diabetes Polyneuropathy. Frontiers in Neurology, 2018, 9, 803.	2.4	33
160	Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641880324.	3.5	16
161	Predictors of response to opicinumab in acute optic neuritis. Annals of Clinical and Translational Neurology, 2018, 5, 1154-1162.	3.7	19
162	An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis. Frontiers in Physiology, 2018, 9, 10.	2.8	8

#	Article	IF	Citations
163	Dual-Tasking in Multiple Sclerosis â€“ Implications for a Cognitive Screening Instrument. Frontiers in Human Neuroscience, 2018, 12, 24.	2.0	13
164	Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion. NeuroImage: Clinical, 2018, 20, 61-70.	2.7	11
165	Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?. Multiple Sclerosis Journal, 2018, 24, 1337-1346.	3.0	18
166	MS-Dokumentation, -Register und -Management. , 2018, , 435-447.		0
167	Long-term safety and tolerability of glatiramer acetate 20 mg in the treatment of relapsing forms of multiple sclerosis. Expert Opinion on Drug Safety, 2017, 16, 247-255.	2.4	24
168	The norepinephrine system shows information-content specific properties during cognitive control â€“ Evidence from EEG and pupillary responses. NeuroImage, 2017, 149, 44-52.	4.2	104
169	Electrocardiographic assessments and cardiac events after fingolimod first dose â€“ a comprehensive monitoring study. BMC Neurology, 2017, 17, 11.	1.8	23
170	Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. Autoimmunity Reviews, 2017, 16, 355-376.	5.8	50
171	Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. Journal of Neuroinflammation, 2017, 14, 41.	7.2	54
172	Treatment optimization in multiple sclerosis: how do we apply emerging evidence?. Expert Review of Clinical Immunology, 2017, 13, 509-511.	3.0	22
173	Adrenal medullary dysfunction as a feature of obesity. International Journal of Obesity, 2017, 41, 714-721.	3.4	21
174	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
175	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 189-199.	10.2	210
176	A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity. Nature Immunology, 2017, 18, 654-664.	14.5	139
177	To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. Expert Review of Neurotherapeutics, 2017, 17, 847-849.	2.8	9
178	Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. Expert Opinion on Pharmacotherapy, 2017, 18, 1553-1556.	1.8	8
179	Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Pharmacotherapy, 2017, 18, 1649-1660.	1.8	44
180	Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Therapeutic Advances in Neurological Disorders, 2017, 10, 343-359.	3.5	85

#	Article	IF	Citations
181	Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 7012.	3.3	4
182	Demands on response inhibition processes determine modulations of theta band activity in superior frontal areas and correlations with pupillometry â€“ Implications for the norepinephrine system during inhibitory control. NeuroImage, 2017, 157, 575-585.	4.2	85
183	Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment. BMC Neurology, 2017, 17, 62.	1.8	8
184	The norepinephrine system affects specific neurophysiological subprocesses in the modulation of inhibitory control by working memory demands. Human Brain Mapping, 2017, 38, 68-81.	3.6	61
185	ActiGait implantable drop foot stimulator in multiple sclerosis: a new indication. Journal of Neurosurgery, 2017, 126, 1685-1690.	1.6	10
186	The norepinephrine system and its relevance for multi-component behavior. NeuroImage, 2017, 146, 1062-1070.	4.2	43
187	Immunomodulatory therapy in 5798 relapsing-remitting multiple sclerosis (RRMS) patients over time under special consideration of switching to oral DMD: A retrospective data analysis. Journal of the Neurological Sciences, 2017, 381, 531.	0.6	0
188	Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up. Frontiers in Physiology, 2017, 8, 778.	2.8	13
189	Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinsonâ€™s Disease (CAPTURE PD): Protocol for a Multicenter Study. Frontiers in Neurology, 2017, 8, 212.	2.4	14
190	Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis. Frontiers in Neuroscience, 2017, 11, 540.	2.8	14
191	Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLoS ONE, 2017, 12, e0173353.	2.5	15
192	Patientsâ€™ preferences for involvement in the decision-making process for treating diabetic retinopathy. BMC Ophthalmology, 2017, 17, 139.	1.4	25
193	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. Journal of Neuroinflammation, 2017, 14, 172.	7.2	16
194	Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures. Frontiers in Neurology, 2017, 8, 703.	2.4	7
195	Response to: S. Sega-Jazbec et al.: â€œManagement of infusion related reactions associated with alemtuzumab in patients with multiple sclerosisâ€•Multiple Sclerosis and Related Disorders 2017. Multiple Sclerosis and Related Disorders, 2017, 17, 177-178.	2.0	3
196	Abstract TP228: Continuous Non-invasive Blood Pressure versus Oscillometric Assessment in Acute Care After Intracerebral Hemorrhage, Intravenous Thrombolysis for Acute Ischemic Stroke. Stroke, 2017, 48, .	2.0	0
197	Limited Time from the Diabetes Patients' Perspective: Need for Conversation with the Eye Specialist. Ophthalmologica, 2016, 236, 154-158.	1.9	0
198	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2016, 73, 1089.	9.0	92

#	Article	IF	Citations
199	6â€sulpho LacNAc⁺ dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system. Neuropathology and Applied Neurobiology, 2016, 42, 394-398.	3.2	4
200	Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS). BMC Neurology, 2016, 16, 109.	1.8	26
201	Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	26
202	Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination. Brain Research, 2016, 1642, 124-130.	2.2	6
203	Comparison of baroreflex sensitivity estimated from ECG Râ€“R and inter-systolic intervals obtained by finger plethysmography and radial tonometry. Journal of Neural Transmission, 2016, 123, 481-490.	2.8	4
204	Laquinimod in the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 701-709.	3.3	5
205	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2973-82.	7.1	157
206	Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. BMC Neurology, 2016, 16, 129.	1.8	30
207	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. BMC Neurology, 2016, 16, 98.	1.8	15
208	Immunomodulatory treatments and cognition in MS. Acta Neurologica Scandinavica, 2016, 134, 55-59.	2.1	14
209	Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ). Journal of Neurology, 2016, 263, 1969-1983.	3.6	16
210	Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurology, 2016, 16, 124.	1.8	79
211	New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. Journal of Neuroinflammation, 2016, 13, 164.	7.2	39
212	The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine, 2016, 14, 81.	5.5	83
213	Therapy satisfaction and adherence in patients with relapsingâ€“remitting multiple sclerosis: the THEPA-MS survey. Therapeutic Advances in Neurological Disorders, 2016, 9, 250-263.	3.5	60
214	Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e228.	6.0	68
215	Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature, 2016, 530, 349-353.	27.8	305
216	QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naÃ¯ve patients, and previously treated patients. Journal of Neurology, 2016, 263, 784-791.	3.6	21

#	Article	IF	Citations
217	Optimizing treatment success in multiple sclerosis. Journal of Neurology, 2016, 263, 1053-1065.	3.6	155
218	Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System. Interactive Journal of Medical Research, 2016, 5, e2.	1.4	44
219	Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive) Tj ETQq1 1 0.784314 rgBT /Overlock 2016, 5, e23.	1.0	11
220	Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms). Value in Health, 2015, 18, A763.	0.3	7
221	PP.41.04. Journal of Hypertension, 2015, 33, e501.	0.5	0
222	Efficacy for remyelination and safety of anti-lingo-1 monoclonal antibody (biib033) in acute optic neuritis: results from the renew study. Journal of the Neurological Sciences, 2015, 357, e14-e15.	0.6	1
223	Pangaea 2.0: State Of The Art Multiple Sclerosis Patient Management In Daily Clinical Practice. A New 3-Year Observational Study Of Patients Receiving Fingolimod. Value in Health, 2015, 18, A686.	0.3	2
224	Confirmed Disability Improvement In Patients With Active Multiple Sclerosis Treated With Fingolimod Versus Brace: A Matched Comparison of Treatments From The Pangaea And Pearl Registry Studies. Value in Health, 2015, 18, A750.	0.3	6
225	Physicianâ€“patient communication skills: e-tools. Neurodegenerative Disease Management, 2015, 5, 51-53.	2.2	0
226	Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsingâ€“remitting multiple sclerosis converting to glatiramer acetate. BMC Neurology, 2015, 15, 189.	1.8	6
227	Insulin is a key determinant of elevated retinal arteriolar flicker response in insulin-resistant individuals. Diabetologia, 2015, 58, 2154-2160.	6.3	3
228	Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology, 2015, 84, 436-437.	1.1	5
229	36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice. Value in Health, 2015, 18, A749.	0.3	10
230	Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECTâ„¢). Neurology and Therapy, 2015, 4, 125-136.	3.2	27
231	Effects of the Peroxisome Proliferator-Activated Receptor-Î³ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial. Cardiology, 2015, 131, 165-171.	1.4	3
232	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. Multiple Sclerosis and Related Disorders, 2015, 4, 83-84.	2.0	7
233	Different responses of the retinal and cutaneous microcirculation to transient dysmetabolic conditions. Atherosclerosis Supplements, 2015, 18, 1-7.	1.2	9
234	Immunoadsorption with regenerating systems in neurological disordersÂâ€“ A single center experience. Atherosclerosis Supplements, 2015, 18, 119-123.	1.2	15

#	Article	IF	Citations
235	Attenuated brain-derived neurotrophic factor and hypertrophic remodelling: the SABPA study. Journal of Human Hypertension, 2015, 29, 33-39.	2.2	16
236	Optimizing therapy early in multiple sclerosis: An evidence-based view. Multiple Sclerosis and Related Disorders, 2015, 4, 460-469.	2.0	83
237	Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system. Atherosclerosis Supplements, 2015, 18, 8-15.	1.2	9
238	Recognition and treatment of autonomic disturbances in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2015, 15, 1189-1203.	2.8	20
239	The PANGAEA study design â€“ a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurology, 2015, 15, 93.	1.8	54
240	Effects of the PPARÎ³ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. Heart and Vessels, 2015, 30, 286-295.	1.2	11
241	Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. Molecular Psychiatry, 2015, 20, 880-888.	7.9	65
242	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinsonâ€™s disease. Journal of Neural Transmission, 2015, 122, 419-425.	2.8	43
243	Local endothelial dysfunction does not affect global endothelial function. Vasa - European Journal of Vascular Medicine, 2015, 44, 277-284.	1.4	1
244	Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. PLoS ONE, 2015, 10, e0138243.	2.5	14
245	Time for Change â€“ Evolution of Real-world Evidence Outcome Measures in Multiple Sclerosis Exemplified by Fingolimod. European Neurological Review, 2015, 9, 136.	0.5	10
246	MS-Dokumentation, MS-Register und MS-Management. , 2015, , 447-459.		0
247	Attenuated NOx responses and myocardial ischemia, a possible risk for structural vascular disease in African men: the SABPA study. Journal of Human Hypertension, 2014, 28, 438-443.	2.2	3
248	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 851-858.	1.9	101
249	Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 754-755.	2.0	2
250	PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study. Multiple Sclerosis and Related Disorders, 2014, 3, 751.	2.0	2
251	Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. European Journal of Endocrinology, 2014, 170, 349-357.	3.7	25
252	A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. Journal of Neurology, 2014, 261, 2101-2111.	3.6	34

#	Article	IF	Citations
253	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 411-418.	1.9	63
254	Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis. Value in Health, 2014, 17, A403.	0.3	0
255	Dendritic cells are specifically affected by different immunomodulatory treatment strategies in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 92-93.	2.3	0
256	Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease. BMC Neurology, 2014, 14, 126.	1.8	5
257	Time matters â€“ Acute stress response and glucocorticoid sensitivity in early multiple sclerosis. Brain, Behavior, and Immunity, 2014, 41, 82-89.	4.1	16
258	Accumulation and therapeutic modulation of 6-sulfo LacNAc ⁺ dendritic cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e33.	6.0	28
259	Seasonal variation of plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
260	Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients â€“ an observational study. Experimental & Translational Stroke Medicine, 2013, 5, 7.	3.2	13
261	Recent perspectives in neurology. Journal of Neural Transmission, 2013, 120, 1-2.	2.8	0
262	Therapeutic Decisions in Multiple Sclerosis. JAMA Neurology, 2013, 70, 1315-24.	9.0	80
263	Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients. Journal of Neural Transmission, 2013, 120, 61-66.	2.8	46
264	Perspectives of an innovative ophthalmological technology: Optical coherence tomography (OCT) â€“ What should be of interest to the neurologist?. Clinical Neurology and Neurosurgery, 2013, 115, S55-S59.	1.4	10
265	Defensive coping facilitates higher blood pressure and early sub-clinical structural vascular disease via alterations in heart rate variability: The SABPA study. Atherosclerosis, 2013, 227, 391-397.	0.8	36
266	Management of fingolimod in clinical practice. Clinical Neurology and Neurosurgery, 2013, 115, S60-S64.	1.4	19
267	Defensive active coping facilitates chronic hyperglycaemia and endothelial dysfunction in African men: The SABPA study. International Journal of Cardiology, 2013, 168, 999-1005.	1.7	5
268	Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. Atherosclerosis Supplements, 2013, 14, 107-113.	1.2	18
269	Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease. Atherosclerosis Supplements, 2013, 14, 135-141.	1.2	5
270	Nocturnal Blood Pressure, 3-Methoxy-4-hydroxyphenylglycol and Carotid Intima-media Thickness: The SABPA Study. Heart Lung and Circulation, 2013, 22, 917-923.	0.4	2

#	Article	IF	Citations
271	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurology, The, 2013, 12, 756-767.	10.2	205
272	Trigonometric regressive spectral analysis: an innovative tool for evaluating the autonomic nervous system. Journal of Neural Transmission, 2013, 120, 27-33.	2.8	23
273	Metabolomic distinction of microvascular effects of lipoprotein apheresisÂâ€“ A pilot study. Atherosclerosis Supplements, 2013, 14, 143-149.	1.2	5
274	Effects of Pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. European Heart Journal, 2013, 34, 2672-2672.	2.2	0
275	Modern communication technology skills of patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1240-1241.	3.0	28
276	Effects of Acute and Chronic Stress on the L-Arginine Nitric Oxide Pathway in Black and White South Africans. Psychosomatic Medicine, 2013, 75, 751-758.	2.0	16
277	Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Multiple Sclerosis Journal, 2013, 19, 1792-1799.	3.0	104
278	Neuroborreliosis during natalizumab treatment in multiple sclerosis. Neurology, 2013, 81, 1012-1014.	1.1	1
279	Cortisol Awakening Response Is Linked to Disease Course and Progression in Multiple Sclerosis. PLoS ONE, 2013, 8, e60647.	2.5	38
280	The sensory channel of presentation alters subjective ratings and autonomic responses toward disgusting stimuliâ€"Blood pressure, heart rate and skin conductance in response to visual, auditory, haptic and olfactory presented disgusting stimuli. Frontiers in Human Neuroscience, 2013, 7, 510.	2.0	40
281	Die Anwendung von Multi-Touch-Gesten in Patientenmanagementsystemen. Xpert Press, 2013, , 301-315.	0.1	0
282	Psychoneuroimmunology - Psyche and Autoimmunity. Current Pharmaceutical Design, 2012, 18, 4485-4488.	1.9	5
283	Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy. Journal of Hypertension, 2012, 30, 543-550.	0.5	40
284	Greater cardiovascular reactivity to a cold stimulus is due to higher cold pain perception in black Africans. Journal of Hypertension, 2012, 30, 2416-2424.	0.5	25
285	Static posturography in aging and Parkinson's disease. Frontiers in Aging Neuroscience, 2012, 4, 20.	3.4	43
286	Improving patient–physician dialog: commentary on the results of the MS Choices survey. Patient Preference and Adherence, 2012, 6, 143.	1.8	19
287	Identifying prodromal Parkinson's disease: Preâ€Motor disorders in Parkinson's disease. Movement Disorders, 2012, 27, 617-626.	3.9	443
288	Autonomic responses to stress in <scp>B</scp>lack versus <scp>C</scp>aucasian <scp>A</scp>fricans: The <scp>SABPA</scp> Study. Psychophysiology, 2012, 49, 454-461.	2.4	14

#	Article	IF	Citations
289	Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study. Journal of Medical Internet Research, 2012, 14, e135.	4.3	75
290	Cardiovascular autonomic testing in extrapyramidal disorders. Journal of the Neurological Sciences, 2011, 310, 129-132.	0.6	15
291	Symptom management in patients with multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, S48-S52.	0.6	56
292	Determination of Baroreflex Sensitivity during the Modified Oxford Maneuver by Trigonometric Regressive Spectral Analysis. PLoS ONE, 2011, 6, e18061.	2.5	20
293	Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders. PLoS ONE, 2011, 6, e18506.	2.5	23
294	Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. Psychoneuroendocrinology, 2011, 36, 1505-1512.	2.7	39
295	Treatment of dysautonomia in extrapyramidal disorders. Journal of Neurology, 2011, 258, 339-345.	3.6	10
296	Seizures Associated with Zoledronic Acid for Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1955-1959.	3.6	26
297	Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report. Multiple Sclerosis Journal, 2011, 17, 245-249.	3.0	15
298	Baroreceptor sensitivity, cardiovascular responses and ECG left ventricular hypertrophy in men: The SABPA study. Blood Pressure, 2011, 20, 355-361.	1.5	20
299	Autonomic Function and Cerebral Autoregulation in Patients Undergoing Carotid Endarterectomy. Circulation Journal, 2010, 74, 2139-2145.	1.6	24
300	Comprehensive autonomic assessment does not differentiate between Parkinsonâ€™s disease, multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission, 2010, 117, 69-76.	2.8	43
301	The cold hand sign in multiple system atrophy: skin perfusion revisited. Journal of Neural Transmission, 2010, 117, 475-479.	2.8	10
302	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology, 2010, 68, 409-411.	5.3	40
303	Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Movement Disorders, 2010, 25, 315-324.	3.9	36
304	Trigonometric Regressive Spectral Analysis Reliably Maps Dynamic Changes in Baroreflex Sensitivity and Autonomic Tone: The Effect of Gender and Age. PLoS ONE, 2010, 5, e12187.	2.5	19
305	Review: Treatment of dysautonomia in extrapyramidal disorders. Therapeutic Advances in Neurological Disorders, 2010, 3, 53-67.	3.5	22
306	CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplantation, 2010, 45, 1489-1496.	2.4	52

#	Article	IF	Citations
307	Cardiovascular autonomic dysfunction in Parkinson's disease. Journal of the Neurological Sciences, 2010, 289, 74-80.	0.6	116
308	LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis, 2010, 213, 212-217.	0.8	10
309	Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis.. Journal of Clinical Oncology, 2010, 28, 3575-3575.	1.6	0
310	Treatment strategies for nonmotor manifestations of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2009, 10, 773-784.	1.8	10
311	Education Research: Cognitive performance is preserved in sleep-deprived neurology residents. Neurology, 2009, 73, e99-e103.	1.1	17
312	Potential side effect of high-dose corticosteroid relapse treatment: acute generalized exanthematous pustulosis (AGEP). Multiple Sclerosis Journal, 2009, 15, 275-277.	3.0	8
313	Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Movement Disorders, 2009, 24, 2136-2142.	3.9	95
314	Valsalva manoeuvre in patients with different Parkinsonian disorders. Journal of Neural Transmission, 2009, 116, 875-880.	2.8	40
315	Pupillary responses to intranasal trigeminal and olfactory stimulation. Journal of Neural Transmission, 2009, 116, 885-889.	2.8	15
316	Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. International Ophthalmology, 2009, 29, 213-224.	1.4	22
317	Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Proteomics - Clinical Applications, 2009, 3, 1273-1287.	1.6	25
318	Ethnicâ€specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function. Obesity, 2009, 17, 2210-2215.	3.0	7
319	Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Multiple Sclerosis Journal, 2009, 15, 752-758.	3.0	54
320	Multiple sclerosis beyond EDSS: depression and fatigue. Journal of the Neurological Sciences, 2009, 277, S37-S41.	0.6	128
321	Effect of BEMER Magnetic Field Therapy on the Level of Fatigue in Patients with Multiple Sclerosis: A Randomized, Double-Blind Controlled Trial. Journal of Alternative and Complementary Medicine, 2009, 15, 507-511.	2.1	34
322	Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atherosclerosis Supplements, 2009, 10, 39-43.	1.2	38
323	Influence of ECG Sampling Frequency on Spectral Analysis of RR Intervals and Baroreflex Sensitivity Using the EUROBAVAR Data set. Journal of Clinical Monitoring and Computing, 2008, 22, 159-168.	1.6	57
324	Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. Journal of Neural Transmission, 2008, 115, 1527-1536.	2.8	43

#	Article	IF	Citations
325	What can we learn from failed clinical trials in multiple sclerosis?. Journal of Neurology, 2008, 255, 97-101.	3.6	2
326	Autonomic dysfunction in different subtypes of multiple system atrophy. Movement Disorders, 2008, 23, 1766-1772.	3.9	34
327	Autonomic dysfunction in patients with progressive supranuclear palsy. Movement Disorders, 2008, 23, 2083-2089.	3.9	31
328	Pharmacokinetic/Pharmacodynamic Modelling of Venlafaxine. Clinical Pharmacokinetics, 2008, 47, 721-731.	3.5	15
329	Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health and Quality of Life Outcomes, 2008, 6, 67.	2.4	59
330	Review: Brainâ€"immune communication psychoneuroimmunology of multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 6-21.	3.0	34
331	The Effects of Venlafaxine on Autonomic Functions in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2007, 27, 687-691.	1.4	34
332	Non-motor dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, 323-332.	2.2	171
333	Stroke-Induced Immunodepression. Stroke, 2007, 38, 770-773.	2.0	417
334	Glatiramer Acetate: Mechanisms of Action in Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 537-570.	2.0	86
335	Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Movement Disorders, 2007, 22, 2123-2126.	3.9	23
336	Intravitreous bevacizumab and blood pressure: does â€˜safeâ€™ mean â€˜safe enoughâ€™?. Acta Ophthalmologica, 2007, 85, 573-574.	0.3	3
337	Glatiramer acetate: Mechanisms of action in multiple sclerosis. Autoimmunity Reviews, 2007, 6, 469-475.	5.8	123
338	A New Line Immunoassay for the Multiparametric Detection of Antiganglioside Autoantibodies in Patients with Autoimmune Peripheral Neuropathies. Annals of the New York Academy of Sciences, 2007, 1109, 256-264.	3.8	35
339	The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects. Clinical Autonomic Research, 2007, 17, 160-164.	2.5	13
340	Psychoneuroimmunology â€“ Cross-talk between the immune and nervous systems. Journal of Neurology, 2007, 254, II8-II11.	3.6	71
341	Multiple sclerosis and the autonomic nervous system. Journal of Neurology, 2006, 253, i21-i25.	3.6	40
342	The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmunity Reviews, 2005, 4, 460-467.	5.8	81

#	Article	IF	Citations
343	Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis. Journal of Neurology, 2005, 252, v38-v45.	3.6	16
344	Autoimmune CD4+ T Cell Memory: Lifelong Persistence of Encephalitogenic T Cell Clones in Healthy Immune Repertoires. Journal of Immunology, 2005, 175, 69-81.	0.8	46
345	Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. Journal of the Neurological Sciences, 2005, 233, 109-112.	0.6	58
346	The Activation Status of Neuroantigen-specific T Cells in the Target Organ Determines the Clinical Outcome of Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 2004, 199, 185-197.	8.5	163
347	Neuroprotection and Glatiramer Acetate: The Possible Role in the Treatment of Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2004, 541, 111-134.	1.6	12
348	Adult polyglucosan body disease. Neurology, 2003, 61, 263-265.	1.1	36
349	Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain, 2002, 125, 2381-2391.	7.6	241
350	Gravesâ€™ disease after treatment with Alemtuzumab for multiple sclerosis. Hormones, 2002, 14, 148-53.	1.9	21
351	Phospholipase A2 degradation products modulate epithelial and stromal 5?-reductase activity of human benign prostatic hyperplasia in vitro. Prostate, 2002, 50, 4-14.	2.3	3
352	Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis. Drug Safety, 2001, 24, 979-990.	3.2	64
353	In vitro modulation of steroid 5Î±-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia. Steroids, 2001, 66, 521-528.	1.8	5
354	Brain structure and neurocognitive function in two professional mountaineers during 35â€‰days severe normobaric hypoxia. European Journal of Neurology, 0, , .	3.3	0
355	OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany. Frontiers in Neurology, 0, 13, .	2.4	4